Articles tagged with Neutralizing Antibodies
Researchers at Rockefeller University have made two fundamental discoveries about broadly neutralizing anti-HIV antibodies, which effectively keep the virus at bay. They found that most antibodies bind to their target in a polyreactive manner, enhancing overall affinity by binding non-specifically to the virion.
Researchers found that HIV can mutate its outer proteins to disguise itself from neutralizing antibodies, allowing it to escape the immune system. In two patients, viruses mutated parts of their outer proteins, interfering with antibody attack or targeting a different protein.
A study by Dan Barouch and colleagues at Beth Israel Deaconess Medical Center found no correlation between Ad5 neutralizing antibodies and T-cell immune responses. The researchers suggest using rare serotype vectors to develop HIV-1 vaccines that are not suppressed by baseline vector-specific neutralizing antibodies.
A team of researchers refuted a popular hypothesis about the failure of the Merck STEP HIV vaccine study by finding no correlation between pre-existing neutralizing antibodies and increased susceptibility to infection. The study analyzed blood samples from participants with varying degrees of pre-existing immunity to Ad5 and found that...
Researchers suggest a promising approach to create an antibody-based HIV vaccine by leveraging naturally occurring broadly neutralizing antibodies. By understanding how these antibodies evolve and persist, scientists aim to develop a vaccine that can prime the body to make protective antibodies before exposure to HIV.
Researchers at Gladstone Institutes have discovered a gene, Apobec3, that controls the production of antibodies neutralizing retroviruses, including HIV. This finding may lead to the development of an HIV vaccine by eliciting neutralizing antibodies.
Scientists have discovered a connection between Apobec3 and the production of neutralizing antibodies against HIV, potentially shedding light on why most people who contract the virus don't develop effective immunity. The study's findings could lead to new insights into developing HIV drugs and vaccines.
Researchers discovered that a specific region of the HIV-1 envelope protein is embedded in the viral membrane, making it difficult to target with antibodies. However, a new approach using antibodies targeting this region could lead to the development of an effective HIV-1 vaccine
Researchers at The Scripps Research Institute have identified an antibody called 4E10 that can neutralize nearly 100 different HIV strains. This breakthrough could lead to the development of a more effective HIV vaccine by targeting this specific epitope.
A study led by Drs. Dennis R. Burton and Ian A. Wilson identified the specific amino acids on gp41 that 4E10 interacts with, revealing its unique ability to target a conserved region near the surface of the virus. This research advances the quest for an HIV-1 vaccine, providing valuable insights into broadly neutralizing antibodies.
Researchers at TSRI describe an unusual antibody configuration that effectively neutralizes HIV by binding to sugars on its surface. This breakthrough could lead to designing an effective AIDS vaccine by stimulating the human immune system to produce similar broadly neutralizing antibodies.
HIV-1 uses a unique 'glycan shield' mechanism to evade antibody attack, continuously changing large sugar molecules on its surface. This allows the virus to outsmart the immune system and escape elimination.
A novel naked DNA vaccination technology has been developed to overcome autoimmune diseases like rheumatoid arthritis and multiple sclerosis. The vaccine introduces engineered genes that neutralize proinflammatory peptides, allowing the immune system to self-regulate its response and prevent disease progression.
Researchers have identified the importance of neutralizing antibodies in preventing HIV infection, with studies showing that these antibodies can prevent infection in primates. Additionally, a study found that vaccines must elicit responses in all three major immune cell subsets to be effective, suggesting that broadly based immunity i...
Scientists from the University of Montana and HHMI successfully produced broadly effective antibodies against HIV by capturing the virus's infective machinery in the moment it fuses with a target cell. The new approach outperforms previous efforts, which only neutralized laboratory-grown strains.
Scientists have discovered that antibodies can recognize the orientation of amino acids, allowing them to bind only with specific handedness. This ability may be key to developing new, effective pharmaceuticals by identifying and sorting out left- and right-handed molecules.